Abstract:Epidemiological, preclinical and cellular studies in the last 5 years have shown that metformin exerts anti-tumoral properties, but its mode of action in cancer remains unclear. Here, we investigated the effects of metformin on a mouse hepatocellular carcinoma (HCC) model and tumor-associated T cell immune responses. Oral metformin administration led to a significant reduction of tumor growth, which was accompanied by decreased interleukin-22 (IL-22). Meanwhile, IL-22-induced STAT3 phosphorylation and upregulation of downstream genes Bcl-2 and cyclin D1 were inhibited by metformin. At the cellular level, metformin attenuated Th1- and Th17-derived IL-22 production. Furthermore, metformin inhibited de novo generation of Th1 and Th17 cells from naive CD4(+) cells. These observations were further supported by the fact that metformin treatment inhibited CD3/CD28-induced IFN- and IL-17A expression along with the transcription factors that drive their expression (T-bet [Th1] and ROR-t [Th17], respectively). The effects of metformin on T cell differentiation were mediated by downregulated STAT3 and STAT4 phosphorylation via the AMP-activated kinase-mammalian target of rapamycin complex 1 pathway. Notably, metformin led to a reduction in glucose transporter Glut1 expression, resulting in less glucose uptake, which is critical to regulate CD4(+) T cell fate. Taken together, these findings provide evidence for the growth-inhibitory and immune-modulatory effects of metformin in HCC and thus, broaden our understanding about the action of metformin in liver cancer treatment.What's new? Over the last decade, metformin, an anti-diabetic drug, has gained significant attention as an anti-cancer drug because of its association with a dramatically decreased risk of some cancers. The underlying mechanisms of action, however, remain largely unknown. Here, using a mouse hepatocellular carcinoma (HCC) model, the authors found an important and previously unidentified effect of metformin with the inhibition of HCC growth through an indirect path mediated by IL-22. The findings also provide evidence for immune-modulatory effects of metformin in HCC. Taken together, these data broaden our current understanding of the mechanisms of action of metformin in liver cancer treatment.

Metformin Attenuates Hepatoma Cell Proliferation by Decreasing Glycolytic Flux Through the HIF-1α/PFKFB3/PFK1 Pathway.

Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling.

Metformin Decreases Il-22 Secretion To Suppress Tumor Growth In An Orthotopic Mouse Model Of Hepatocellular Carcinoma

Metformin Mediates Resensitivity to 5-Fluorouracil in Hepatocellular Carcinoma Via the Suppression of YAP.

Metformin Suppresses Hepatocellular Carcinoma Cell Growth Through Induction of Cell Cycle G1/G0 Phase Arrest and P21(Cip) and P27(Kip) Expression and Downregulation of Cyclin D1 in Vitro and in Vivo

In Vitro and in Vivo Antitumoral Action of Metformin on Hepatocellular Carcinoma

[Metformin suppresses hypoxia-inducible factor-1 α expression in cancer-associated fibroblasts to block tumor-stromal cross-talk in breast cancer]

Metformin exerts anti-tumor effects via Sonic hedgehog signaling pathway by targeting AMPK in HepG2 cells.

Metformin inhibits growth of human non‑small cell lung cancer cells via liver kinase B‑1‑independent activation of adenosine monophosphate‑activated protein kinase

Metformin targets liver tumor-initiating cells through the PI3K/Akt/mTOR survival pathway

Metformin decreases <i>Cyp26a1</i> to prevent hepatocarcinogenesis through down- regulating CD8<sup>+</sup> T cells

Metformin Induces Autophagy via the AMPK-mTOR Signaling Pathway in Human Hepatocellular Carcinoma Cells

Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα

Metformin Inhibits Hepatocellular Carcinoma Development by Inducing Apoptosis and Pyroptosis Through Regulating FOXO3

Metformin sensitises hepatocarcinoma cells to methotrexate by targeting dihydrofolate reductase

Basal Autophagy and Feedback Activation of Akt Are Associated with Resistance to Metformin-Induced Inhibition of Hepatic Tumor Cell Growth

Metformin decreases Cyp26a1 to prevent hepatocarcinogenesis through down- regulating CD8+ T cells

Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration

Transcriptome Analysis of Liver Cancer Cell Huh-7 Treated With Metformin

Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer.

Metabolic Switching in the Hypoglycemic and Antitumor Effects of Metformin on High Glucose Induced HepG2 Cells